…Some occurred in genes already known to be associated with a genetic predisposition to ovarian cancer, such as BRCA1and BRCA2, while others occurred in genes that have never been linked…
…are more likely to carry the BRCA1 and BRCA2 mutations that increase breast and ovarian cancer risk. Consequently, these families often have sisters, daughters, cousins, etc. with breast and/or ovarian…
…in BRCA1 or BRCA2 are at substantially elevated risk for ovarian cancer. To understand what percentage of women with high risk family histories know their risk is elevated, researchers at…
…EOC and 2,772 controls from a case-control study, as well as 2,000 unaffected BRCA1/2-negative women from the U.K. Familial Ovarian Cancer Screening Study. OCRF SAC member Kunle Odunsi, MD, PhD,…
…and Elizabeth on the day Elizabeth was tested for BRCA mutations An opportunity to contribute came about when Emma started making bracelets earlier this year and a few friends expressed…
…impacted your family? Cancer does not just affect the patient; it includes family and friends. Even though I didn’t have a BRCA1 or BRCA2 mutation that could increase ovarian cancer…
…published on July 18th, does not apply to women who are positive for BRCA1 and BRCA2 genetic mutations, who have a higher risk of developing ovarian cancer. There are two…
…ovarian cancer, as well as other women’s cancers. He has helped define the role of tumor suppressors and oncogenes in these malignancies, most notably the p53, BRCA1 and BRCA2 tumor…
…in the TGCA-OV set. To gain insights around treatment resistance, particular attention was paid to homologous recombination-deficient (HRD) disease status, presence of BRCA1 or BRCA2 mutations, and associated response to…
…primary recommendation for women of high risk, specifically after having children, before the age of 40 for BRCA1 carriers, and before 45 years of age for BRCA2 carriers. “Up until…
…in their ability to kill cancer cells. PARP inhibitors are a class of drugs that have shown promising results against ovarian cancer in women with BRCA1 and BRCA2 gene mutations….
…cancers respond to particular treatments or better tolerate treatment at a lower starting dose (predictive biomarkers). Biomarkers can be mutation carrier status (BRCA1 or 2+), molecular characteristics of tumors (HRD,…
Get email updates about research news, action alerts, and ways to join the fight.
